Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke

Journal of Neurosurgery

Volumn 86, Issue 1, 1997, Pages 139-142

  Bednar, Martin M ^a   Gross, Cordell E ^b   Russell, Sheila R ^b   Short, David ^b   Giclas, Patricia C ^b  

^a UNIVERSITY OF VERMONT   (United States)

^b NONE

Author keywords

cerebral ischemia; complement; inflammation; neutrophil; rabbit; tissue plasminogen activator

Indexed keywords

COMPLEMENT COMPONENT C5; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; BRAIN ISCHEMIA; CAROTID ENDARTERECTOMY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; HEMOLYSIS; INTERNAL CAROTID ARTERY; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY; STROKE; THROMBOEMBOLISM; TISSUE INJURY;

EID: 0031036287     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.1997.86.1.0139     Document Type: Article

References (29)

1. Bednar MM, Dooley RH, Zamani M, et al: Neutrophil and platelet activity and quantification following delayed tPA therapy in a rabbit model of thromboembolic stroke. J Thromb Thromb 1:179-185, 1994
2. Bednar MM, McAuliffe T. Raymond S. et al: Tissue plasminogen activator reduces brain injury in a rabbit model of thromboembolic stroke. Stroke 21:1705-1709, 1990
3. Bennett WR, Yawn DH, Migliore PJ, et al: Activation of the complement system by recombinant tissue plasminogen activator. J Am Coll Cardiol 10:627-632, 1987
4. Bishop MJ, Giclas PC, Guidotti SM, et al: Complement activation is a secondary rather than a causative factor in rabbit pulmonary anterior ischemia/reperfusion injury. Am Rev Respir Dis 143:386-390, 1991
5. Craddock PR, Hammerschmidt D, White JG, et al: Complement (CSa)-induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia. J Clin Invest 60:260-264, 1977
6. Craddock PR, Hammerschmidt DE, Moldow CF, et al: Granulocyte aggregation as a manifestation of membrane interactions with complement: possible role in leukocyte margination. microvascular occlusion, and endothelial damage. Semin Hematol 16:140-147, 1979
7. Davis WD, Brey RL: Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Rheumatol 10:455-460, 1992
8. del Balzo UH, Levi R, Policy MJ: Cardiac dysfunction caused by purified human C3a anaphylatoxin. Proc Natl Acad Sci USA 82:886-890, 1985
9. Fernandez HN, Henson PM, Otani A, et al: Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under simulated in vivo conditions. J Immunol 120:109-115, 1978
10. Giclas PC, Keeling PJ, Henson PM: Isolation and characterization of the third and fifth components of rabbit complement. Mol Immunol 18:113-123, 1981
11. Gross CE, Bednar MM, Howard DB, et al: Transforming growth factor-β1 reduces infarct size after experimental cerebral ischemia in a rabbit model. Stroke 24:558-562, 1993
12. Hill JH, Ward PA: The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med 133:885-900, 1971
13. Hoffman SA, Arbogast DN, Day TT, et al: Permeability of the blood cerebrospinal fluid barrier during acute immune complex disease. J Immunol 130:1695-1698, 1983
14. Homeister JW, Satoh P, Lucchesi BR: Effects of complement activation in the isolated heart. Role of the terminal complement components. Circ Res 71:303-319, 1992
15. Levine SR, Brott TG: Thrombolytic therapy in cerebrovascular disorders. Prog Cardiovasc Dis 34:235-262, 1992
16. Linington C, Lassmann H, Morgan BP, et al: Immunohistochemical localisation of terminal complement component C9 in experimental allergic encephalomyelitis. Acta Neuropathol 79:78-85, 1989
17. Maroko RP, Carpenter CB, Chiariello M, et al: Reduction by cobra venom factor of myocardial necrosis after coronary anterior occlusion. J Clin Invest 61:661-670, 1978
18. Martin SE, Chenoweth DE, Engler RL, et al: C5a decreases regional coronary blood flow and myocardial function in pigs: implications for a granulocyte mechanism. Circ Res 63: 483-491, 1988
19. McGeer PL, Akiyama H, Itagaki S, et al: Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett 107:341-346, 1989
20. Pinckard RN, O'Rourke RA, Crawford MH, et al: Complement localization and mediation of ischemic injury in baboon myocardium. J Clin Invest 66:1050-1056, 1980
21. Podack ER, Tschopp J: Membrane attack by complement. Mol Immunol 21:589-603, 1984
22. Rabinovici R, Yeh CG, Hillegass LM, et al: Role of complement in endotoxin/platelet-activating factor-induced lung injury. J Immunol 149:1744-1750, 1992
23. Rebhun H, Madorsky JGB, Glovsky MM: Proteins of the complement system and acute phase reactants in sera of patients with spinal cord injury. Ann Allergy 66:335-338, 1991
24. Rossen RD, Swain JL, Michael LH, et al: Selective accumulation of the first component of complement and leukocytes in ischemic canine heart muscle. A possible initiator of an extra myocardial mechanism of ischemic injury. Cire Res 57: 119-130, 1985
25. Sanders ME, Koski CL, Robbins D, et al: Activated terminal complement in cerebrospinal fluid in Guillain-Barré syndrome and multiple sclerosis. J Immunol 136:4456-4459, 1986
26. Seifert PS, Hansson GK: Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis 9: 802-811, 1989
27. Stahl GL, Fletcher MP, Amsterdam EA, et al: Role of granulocytes and C5a in myocardial response to zymosan-activated serum. Am J Physiol 261:H29-H37, 1991
28. Weetman AP, Cohen SB, Oleesky DA, et al: Terminal complement complexes and C1/C1 inhibitor complexes in autoimmune thyroid disease. Clin Exp Immunol 77:25-30, 1989
29. Wiggins RC, Giclas PC, Henson PM: Chemotactic activity generated from the fifth component of complement by plasma Kallikrein of the rabbit. J Exp Med 153:1391-1404, 1981